[1]王 震.利培酮在难治性分裂情感性精神病中的应用[J].医学信息,2023,36(01):144-147.[doi:10.3969/j.issn.1006-1959.2023.01.030]
　WANG Zhen.Application of Risperidone in Refractory Schizoaffective Psychosis[J].Journal of Medical Information,2023,36(01):144-147.[doi:10.3969/j.issn.1006-1959.2023.01.030]
点击复制

利培酮在难治性分裂情感性精神病中的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年01期
页码:
144-147
栏目:
药物与临床
出版日期:
2023-01-01

文章信息/Info

Title:
Application of Risperidone in Refractory Schizoaffective Psychosis
文章编号:
1006-1959（2023）01-0144-04
作者:
王 震
（佳木斯精神病人福利院药剂科，黑龙江 佳木斯 154002）
Author(s):
WANG Zhen
(Pharmaceutical Department of Jiamusi Psychiatric Welfare Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
分裂情感性精神病; 利培酮; 精神分裂性症状; 情感性症状; 生活质量
Keywords:
Schizoaffective psychosis; Risperidone; Schizophrenia symptoms; Emotional symptoms; Quality of life
分类号:
R749.4
DOI:
10.3969/j.issn.1006-1959.2023.01.030
文献标志码:
A
摘要:
目的 研究利培酮在难治性分裂情感性精神病（SAP）中的应用价值。方法 将2020年2月-2021年12月佳木斯精神病人福利院收治的58例难治性SAP患者，按照随机数字表法分为对照组与观察组，对照组（29例）给予碳酸锂治疗，观察组（29例）在对照组基础上加用利培酮治疗，比较两组精神分裂性症状[阳性症状评定量表（SAPS）]、情感性症状[Bech-Rafaelsen躁狂量表（BRMS）、Beck抑郁问卷（BDI）]、血清生化指标[5-羟色胺（5-HT）、多巴胺（DA）、脑源性神经营养因子（BDNF）]、生活质量[健康调查简表（SF-36）]。结果 两组治疗后SAPS评分（幻觉、妄想、怪异行为、阳性思维形式障碍）均有下降且观察组低于对照组（P＜0.05）；两组治疗后BRMS、BDI评分均有下降，且观察组低于对照组（P＜0.05）；两组治疗后5-HT、DA、BDNF水平均有升高，且观察组高于对照组（P＜0.05）；两组治疗后SF-36评分均有升高，且观察组高于对照组（P＜0.05）。结论 将利培酮应用于难治性SAP治疗中，可改善患者精神分裂性症状与情感性症状，调节其神经递质水平，促使生活质量提升。
Abstract:
Objective To study the application value of risperidone in refractory schizoaffective psychosis (SAP).Methods A total of 58 patients with refractory SAP admitted to Jiamusi Psychiatric Hospital from February 2020 to December 2021 were divided into control group and observation group according to the random number table method. The control group (29 cases) was treated with lithium carbonate, and the observation group (29 cases) was treated with risperidone on the basis of the control group. The schizophrenia symptoms [Scale for the Assessment of Positive Symptoms (SAPS)], emotional symptoms [Bech-Rafaelsen Mania Scale (BRMS), Beck Depression Inventory (BDI)], serum biochemical indexes [5-hydroxytryptamine (5-HT), dopamine (DA), brain-derived neurotrophic factor (BDNF)] and quality of life [Short Form-36 Health Survey (SF-36)] were compared between the two groups.Results After treatment, the SAPS scores (hallucinations, delusions, bizarre behaviors, positive thinking disorder) of the two groups were decreased, and those in the observation group were lower than those in the control group (P<0.05). After treatment, the BRMS and BDI scores of the two groups decreased, and those in the observation group were lower than those in the control group (P<0.05). After treatment, the levels of 5-HT, DA and BDNF in the two groups increased, and those in the observation group were higher than those in the control group (P<0.05). The SF-36 scores of the two groups increased after treatment, and those in the observation group were higher than those in the control group (P<0.05).Conclusion The application of risperidone in the treatment of refractory SAP can improve the schizophrenic symptoms and emotional symptoms of patients, regulate the level of neurotransmitters, and improve the quality of life.

参考文献/References:

[1]李刚,徐兴雯,张雪.精神分裂症与双相情感障碍患者认知功能受损特点研究[J].精神医学杂志,2019,32(5):340-343.[2]Schulmann A,Marenco S,Akula N,et al.Inferred Brain Cell-Type Shifts Accompany Schizophrenia and Bipolar Disorder and Differentially Correlate With Antipsychotic Drug Exposure[J].Biological Psychiatry,2021,89(9):S118-S119.[3]黄惠红,陈结南.碳酸锂联合富马酸喹硫平治疗双相情感障碍躁狂发作的疗效及对认知功能的影响[J].海南医学,2021,32(18):2345-2348.[4]段海水,吕贝,黄超.碳酸锂联合喹硫平治疗双相情感障碍的临床研究[J].安徽医药,2018,22(4):746-749.[5]何思维,方蓉.氯氮平联合利培酮对老年精神分裂症阳性症状患者血清T淋巴细胞亚群及炎症因子水平的影响[J].医学临床研究,2018,35(8):1588-1590.[6]余佳,罗明,刘鹏,等.利培酮联合齐拉西酮治疗精神分裂症后抑郁患者的疗效分析[J].西部医学,2019,31(10):1582-1585,1590.[7]李韧之,赵淑娟,王学升,等.氯氮平与舒必利对老年精神分裂症阳性症状疗效及安全性对照研究[J].精神医学杂志,2017,30(2):134-136.[8]马建英,杨勇.富马酸喹硫平片联合碳酸锂对双相情感障碍躁狂发作患者认知功能的影响[J].检验医学与临床,2018,15(2):195-197,201.[9]刘奇勤,武厚,刘明矾.情绪调节状态困难量表的修订及信效度检验[J].中国学校卫生,2017,38(10):1571-1574.[10]王继红,张文静,许立红.帕利哌酮对首次发作精神分裂症患者精神病症状及生活质量的影响[J].医药导报,2018,37(7):852-855.[11]Prabhakaran S,Nagarajan P,Varadharajan N,et al.Relationship Between Quality of Life and Social Support Among Patients with Schizophrenia and Bipolar Disorder: A Cross-Sectional Study[J].Journal of Psychosocial Rehabilitation and Mental Health,2021,8(2):137-145.[12]周绍宇,靳西龙,冯振晓,等.碳酸锂缓释片治疗双相情感障碍的躁狂发作的疗效探讨[J].中国药物与临床,2019,19(19):3282-3285.[13]赵娜,张娟.他莫昔芬和碳酸锂治疗儿童和青少年急性躁狂症的疗效[J].神经损伤与功能重建,2017,12(5):455-456,466.[14]Jauhar S,Nour MM,Veronese M,et al.A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia[J].JAMA Psychiatry,2017,74(12):1206-1213.[15]侯媛媛.齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性分析[J].现代中西医结合杂志,2017,26(3):277-279.[16]黄雪萍,张涛,黄金园,等.氟西汀联用利培酮对精神分裂症患者焦虑、抑郁状态的影响[J].国际精神病学杂志,2018,45(3):452-455.[17]于雪竹,刘伟,崔利军.小剂量利培酮联合拉莫三嗪治疗双相抑郁发作的临床疗效及安全性评价[J].中国地方病防治杂志,2017,32(12):1439,1441.[18]张纾,林强,孙立伟,等.652例碳酸锂不良反应报告分析[J].中国药物警戒,2018,15(84):234-239.[19]Kantrowitz JT.Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches[J].CNS Drugs,2020,34(5):947-959.[20]孔令光,张伟,徐大利,等.帕利哌酮和利培酮对精神分裂症患者脑源性神经营养因子与事件相关电位N400的影响[J].中国新药与临床杂志,2018,37(5):304-308.

相似文献/References:

[1]鲁从林,王先丹,杨遂平,等.奥氮平治疗老年痴呆伴精神行为障碍的临床疗效观察[J].医学信息,2018,31(01):138.[doi:10.3969/j.issn.1006-1959.2018.01.053]
　LU Cong-lin,WANG Xian-dan,YANG Sui-ping,et al.The Clinical Efficacy of Olanzapine in the Treatment of Alzheimer's Disease with Mental Behavior Disorder[J].Journal of Medical Information,2018,31(01):138.[doi:10.3969/j.issn.1006-1959.2018.01.053]
[2]蔡 枫,姚雪阳.利培酮与奥氮平治疗酒精所致精神和行为障碍的临床研究[J].医学信息,2018,31(03):137.[doi:10.3969/j.issn.1006-1959.2018.03.048]
　CAI Feng,YAO Xue-yang.Clinical Study of Risperidone and Olanzapine in the Treatment of Alcohol-induced Mental and Behavioral Disorders[J].Journal of Medical Information,2018,31(01):137.[doi:10.3969/j.issn.1006-1959.2018.03.048]
[3]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
　CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Journal of Medical Information,2018,31(01):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
[4]廖鸿钊,钟建辉.氯氮平联合阿立哌唑、利培酮治疗难治性精神分裂症的疗效及对患者糖脂代谢水平的影响[J].医学信息,2022,35(09):141.[doi:10.3969/j.issn.1006-1959.2022.09.035]
　LIAO Hong-zhao,ZHONG Jian-hui.Clinical Efficacy of Clozapine Combined with Aripiprazole and Risperidone in the Treatment of Treatment Resistant Sehizophrenia and its Effect on Glucose and Lipid Metabolism[J].Journal of Medical Information,2022,35(01):141.[doi:10.3969/j.issn.1006-1959.2022.09.035]
[5]孙来顺.氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响[J].医学信息,2022,35(10):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
　SUN Lai-shun.Effects of Amisulpride and Risperidone on Endocrine And Glucose and Lipid Metabolism in Patients with Schizophrenia[J].Journal of Medical Information,2022,35(01):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
[6]周小琳,陈雪贞,李栋方,等.注射用鼠神经生长因子联合利培酮治疗儿童孤独症的 临床疗效分析[J].医学信息,2018,31(17):63.[doi:10.3969/j.issn.1006-1959.2018.17.019]
　ZHOU Xiao-lin,CHEN Xue-zhen,LI Dong-fang,et al.Clinical Efficacy of Injection of Mouse Nerve Growth Factor Combined with Risperidone in the Treatment of Childhood Autism[J].Journal of Medical Information,2018,31(01):63.[doi:10.3969/j.issn.1006-1959.2018.17.019]
[7]段宝珍,董晓明.婴儿误服利培酮中毒并抢救成功1例报道[J].医学信息,2020,33(23):190.[doi:10.3969/j.issn.1006-1959.2020.23.059]
[8]孙来顺.氨磺必利与利培酮治疗精神分裂症阴性症状的疗效比较[J].医学信息,2022,35(07):121.[doi:10.3969/j.issn.1006-1959.2022.07.030]
　SUN Lai-shun.Comparison of Therapeutic Effects of Amisulpride and Risperidone on Negative Symptoms of Schizophrenia[J].Journal of Medical Information,2022,35(01):121.[doi:10.3969/j.issn.1006-1959.2022.07.030]
[9]田会凤.利培酮联合丙戊酸钠治疗精神分裂症攻击行为的效果及安全性[J].医学信息,2023,36(21):134.[doi:10.3969/j.issn.1006-1959.2023.21.031]
　TIAN Hui-feng.Effect and Safety of Risperidone Combined with Sodium Valproate in the Treatment of Aggressive Behavior of Schizophrenia[J].Journal of Medical Information,2023,36(01):134.[doi:10.3969/j.issn.1006-1959.2023.21.031]

更新日期/Last Update: 1900-01-01